Literature DB >> 8387161

Repeated L-dopa administration reduces the ability of dopamine storage and abolishes the supersensitivity of dopamine receptors in the striatum of intact rat.

M Murata1, I Kanazawa.   

Abstract

The "wearing-off" phenomenon is a clinically recognized adverse effect of long-term L-DOPA therapy in Parkinson's disease. Several causes of this phenomenon have been proposed, but no direct evidence has yet been obtained. The present study was therefore conducted to investigate the effects of long-term L-DOPA administration on the dopamine system. We examined in rats the time course of the levels of L-DOPA and its metabolites in the serum and striatum, the activities of tyrosine hydroxylase and catechol O-methyltransferase, and the D1 and D2 dopamine receptor bindings in the striatum until 12 h after the final dose on the 28th day of repeated oral L-DOPA administration, and compared the results with those after a single L-DOPA administration. The results revealed that long-term L-DOPA administration induced (1) acceleration of DOPA absorption at the gut and the blood-brain barrier, (2) reduction of dopamine retention in the striatum, and (3) loss of "supersensitive response" of dopamine receptors. "Supersensitive response" induced by single L-DOPA administration was preceded by the increase of D1 messenger RNA. We suggest that these changes after long-term L-DOPA administration are causes of the "wearing-off" phenomenon in Parkinson's disease.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8387161     DOI: 10.1016/0168-0102(93)90004-a

Source DB:  PubMed          Journal:  Neurosci Res        ISSN: 0168-0102            Impact factor:   3.304


  7 in total

1.  Compensatory weight gain due to dopaminergic hypofunction: new evidence and own incidental observations.

Authors:  Julia Reinholz; Oliver Skopp; Caterina Breitenstein; Iwo Bohr; Hilke Winterhoff; Stefan Knecht
Journal:  Nutr Metab (Lond)       Date:  2008-12-01       Impact factor: 4.169

2.  Chronic levodopa therapy enhances dopa absorption: contribution to wearing-off.

Authors:  M Murata; H Mizusawa; H Yamanouchi; I Kanazawa
Journal:  J Neural Transm (Vienna)       Date:  1996       Impact factor: 3.575

3.  Prefrontal dopaminergic receptor abnormalities and executive functions in Parkinson's disease.

Authors:  Ji Hyun Ko; Francesca Antonelli; Oury Monchi; Nicola Ray; Pablo Rusjan; Sylvain Houle; Anthony E Lang; Leigh Christopher; Antonio P Strafella
Journal:  Hum Brain Mapp       Date:  2012-02-14       Impact factor: 5.038

Review 4.  Dopamine- or L-DOPA-induced neurotoxicity: the role of dopamine quinone formation and tyrosinase in a model of Parkinson's disease.

Authors:  Masato Asanuma; Ikuko Miyazaki; Norio Ogawa
Journal:  Neurotox Res       Date:  2003       Impact factor: 3.911

5.  Age-related decrease in responsiveness to L-DOPA is not due to changes in dopamine receptor mRNAs or G protein mRNAs.

Authors:  M Murata; Y Aihara; H Yamanouchi; S Yamada; I Kanazawa
Journal:  J Neural Transm (Vienna)       Date:  1996       Impact factor: 3.575

6.  Relationship Between L-DOPA-Induced Reduction in Motor and Exploratory Activity and Striatal Dopamine D2 Receptor Binding in the Rat.

Authors:  Susanne Nikolaus; Markus Beu; Maria A de Souza Silva; Joseph P Huston; Hubertus Hautzel; Claudia Mattern; Christina Antke; Hans-Wilhelm Müller
Journal:  Front Behav Neurosci       Date:  2016-01-06       Impact factor: 3.558

7.  Effects of daily L-dopa administration on learning and brain structure in older adults undergoing cognitive training: a randomised clinical trial.

Authors:  Alexander V Lebedev; Jonna Nilsson; Joanna Lindström; William Fredborg; Ulrika Akenine; Carolina Hillilä; Pia Andersen; Gabriela Spulber; Elizabeth C M de Lange; Dirk-Jan van den Berg; Miia Kivipelto; Martin Lövdén
Journal:  Sci Rep       Date:  2020-03-23       Impact factor: 4.379

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.